OSR Health (OSRHW) Total Non-Current Liabilities (2023 - 2026)
OSR Health (OSRHW) posted Total Non-Current Liabilities of $44.7 million for Q1 2026, up 1.2% sequentially from $44.2 million in Q4 2025, and up 5.83% YoY from $42.3 million in Q1 2025.
OSR Health (OSRHW) Total Non-Current Liabilities (2023 - 2026) Analysis & Trends
OSR Health has reported Total Non-Current Liabilities for 4 years, with the latest figure at $44.7 million in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 5.83% year-over-year to $44.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $44.7 million (up 5.83% YoY) and the FY2025 annual result came in at $44.2 million, up 37.99% from the prior year.
- Total Non-Current Liabilities climbed to $44.7 million in Q1 2026 per OSRHW's latest filing, from $44.2 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $46.3 million in Q2 2025 and troughed at $4.1 million in Q4 2023.
- A 4-year average of $36.7 million and a median of $43.1 million in 2025 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2024 and 2026: Total Non-Current Liabilities jumped 682.5% in 2024, then advanced 5.83% in 2026.
- Over 4 years, Total Non-Current Liabilities stood at $4.1 million in 2023, then surged by 682.5% to $32.0 million in 2024, then soared by 37.99% to $44.2 million in 2025, then rose by 1.2% to $44.7 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $44.7 million, $44.2 million, and $43.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.97 Bn | 131.12 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.15 Bn | 77.15 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 62.84 Bn | 57.65 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 55.74 Bn | 50.60 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.53 Bn | 36.43 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.32 Bn | 8.93 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 9.32 Bn |
| 9 | Insmed | 26.99 Bn | 25.83 Bn | 358.27 Mn | 1.17 Bn |
| 10 | OSR Health | 1.40 Mn | 20.39 Mn | 86,605.00 | 41.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.73 Mn |
| Dec 31, 2025 | 44.20 Mn |
| Sep 30, 2025 | 43.13 Mn |
| Jun 30, 2025 | 46.26 Mn |
| Mar 31, 2025 | 42.27 Mn |
| Dec 31, 2024 | 32.03 Mn |
| Dec 31, 2023 | 4.09 Mn |